Several completed or ongoing phase I to III clinical trials investigating the effects of alisertib, a selective, small‐molecule AURKA inhibitor, in advanced solid tumors and hematologic malignancies have shown some promising results [19, 20, 21, 22, 23, 24, 25]. This evidence concerns the gene AURKA and hematologic disorder.